Related Experiment Video

Updated: Sep 18, 2025

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.7K

Statin versus no statin after treatment with pipeline embolization device for intracranial aneurysms: a meta-analysis

Nathalia Soares Barbosa1, Felipe Araujo Gouhie2, Bezalel Hakkeem3

  • 1Escola Superior de Ciências da Santa Casa de Misericórdia de Vitória, Vitória ES, Brazil.

Arquivos De Neuro-Psiquiatria
|June 21, 2025
PubMed

Insights

Statin therapy may reduce hemorrhagic complications following pipeline embolization device (PED) treatment for brain aneurysms. However, no significant differences were observed in aneurysm occlusion rates or ischemic complications.

Area of Science:

  • Neurology
  • Cardiovascular Research
  • Medical Interventions

Background:

  • Statin therapy is known to improve outcomes for cerebral aneurysms treated with coil embolization or surgical clipping.
  • The efficacy of statins in patients undergoing treatment with pipeline embolization device (PED) for intracranial aneurysms remains unclear.

Purpose of the Study:

  • To evaluate the impact of statin therapy on hemorrhagic and ischemic complications.
  • To assess the effect of statins on the complete occlusion rate of aneurysms treated with PED.

Main Methods:

  • A systematic literature search was conducted in PubMed, Embase, and Cochrane Library databases up to November 2024.
  • Observational studies comparing statin versus no statin therapy after PED treatment were included.
  • Data from four studies involving 2,822 patients and 3,063 aneurysms were analyzed.

Main Results:

  • Statin use was associated with a significant reduction in total hemorrhagic complications (RR=0.50; 95% CI: 0.29-0.85).
  • No significant differences were found in complete aneurysm occlusion rates (RR=0.94; 95% CI: 0.88-1.00) or total ischemic complications (RR=1.48; 95% CI: 1.06-2.07).
  • A propensity score-matched analysis did not confirm the reduction in hemorrhagic complications (RR=0.50; 95% CI: 0.24-1.07).

Conclusions:

  • Statin use may decrease hemorrhagic complications after pipeline embolization device treatment for intracranial aneurysms.
  • The findings regarding reduced hemorrhagic complications should be interpreted with caution due to study limitations.
  • No significant differences in complete occlusion rates or ischemic complications were observed between statin and non-statin groups.

More Related Videos

Using a Cell-Tracer Injection to Investigate the Origin of Neointima-Forming Cells in a Rat Saccular Side Wall Model05:41

Using a Cell-Tracer Injection to Investigate the Origin of Neointima-Forming Cells in a Rat Saccular Side Wall Model

Published on: March 16, 2022

2.4K
Combination of High Ligation and Intraoperative Embolization using Polidocanol for Treatment of Varicoceles02:58

Combination of High Ligation and Intraoperative Embolization using Polidocanol for Treatment of Varicoceles

Published on: December 22, 2023

493

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
42
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
890
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
655
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
34
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
260
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
48